This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

31 Oct 2011

Pfizer Completes Acquisition of Icagen

Pfizer has completed its acquisition of Icagen. Icagen is now a wholly-owned subsidiary of Pfizer.

American pharmaceutical corporation Pfizer Inc. has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer.


Under the terms of the transaction, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6.00 in cash, without interest thereon, and less any applicable withholding and transfer taxes.


Icagen is now part of Pfizer's Worldwide Research and Development organization, and will be integrated into Neusentis, Pfizer's Research Unit encompassing Pain, Sensory Disorders and Regenerative Medicine.

Related News